Regeneron Pharmaceuticals Inc (REGN) Stock Analysis
$REGN · HEALTHCARE · BIOTECHNOLOGY
Regeneron Pharmaceuticals (REGN), a BIOTECHNOLOGY company, has a market capitalization of about $93.91B and trades at 19.0x trailing earnings.
Price
$907.95
Market cap
$93.91B
P/E ratio
19.0x
Dividend yield
0.47%
About Regeneron Pharmaceuticals Inc
Regeneron Pharmaceuticals, Inc. is an American biotechnology company headquartered in Westchester County, New York. Originally focused on neurotrophic factors and their regenerative capabilities, giving rise to its name, the company then branched out into the study of both cytokine and tyrosine kinase receptors.
How StockWorthy values REGN
StockWorthy forecasts Regeneron Pharmaceuticals Inc's revenue, operating profitability, reinvestment (capital expenditure, depreciation and working capital) and unlevered free cash flow, then discounts those cash flows using a normalized cost of capital built from REGN's size, profitability and balance-sheet risk. Terminal growth is adjusted to reflect the company's mature growth profile rather than a fixed number. The model presents bear, base and bull scenarios, and every key assumption stays transparent and adjustable in the full StockWorthy analysis. Results are educational and not investment advice.
Related stocks
See REGN's Fair Value
Create a free account to view Regeneron Pharmaceuticals Inc's base-case fair value, the bear–bull modeled range, and every assumption behind them. Free accounts include 5 stock valuations per month — plus Advanced DCF models, financial charts, dividends, and peer analysis.